Abstract: In order to provide the anti-retrovirus active compound with low anti-coagulant action and low cytotoxicity, compounds comprising glycoside or the salt thereof wherein lipid is linked to position 2 of sialic acid having all hydroxyl groups at positions 4, 7, 8 and 9 completely sulfated, or KDN (2-keto-3-deoxy-D-glycero-2-nononic acid) having all hydroxyl groups at positions 4, 5, 7, 8 and 9 completely sulfated are provided.

Abstract: In order to provide the anti-retrovirus active compound with low anti-coagulant action and low cytotoxicity, compounds comprising glycoside or the salt thereof wherein lipid is linked to position 2 of sialic acid having all hydroxyl groups at positions 4, 7, 8 and 9 completely sulfated, or KDN (2-keto-3-deoxy-D-glycero-2-nononic acid) having all hydroxyl groups at positions 4, 5, 7, 8 and 9 completely sulfated are provided.

Abstract: In order to provide the anti-retrovirus active compound with low anti-coagulant action and low cytotoxicity, compounds comprising glycoside or the salt thereof wherein lipid is linked to position 2 of sialic acid having all hydroxyl groups at positions 4, 7, 8 and 9 completely sulfated, or KDN (2-keto-3-deoxy-D-glycero-2-nononic acid) having all hydroxyl groups at positions 4, 5, 7, 8 and 9 completely sulfated are provided.

Abstract: In order to provide the anti-retrovirus active compound with low anti-coagulant action and low cytotoxicity, compounds comprising glycoside or the salt thereof wherein lipid is linked to position 2 of sialic acid having all hydroxyl groups at positions 4, 7, 8 and 9 completely sulfated, or KDN (2-keto-3-deoxy-D-glycero-2-nononic acid) having all hydroxyl groups at positions 4, 5, 7, 8 and 9 completely sulfated are provided.

Abstract: In order to provide the anti-retrovirus active compound with low anti-coagulant action and low cytotoxicity, compounds comprising glycoside or the salt thereof wherein lipid is linked to position 2 of sialic acid having all hydroxyl groups at positions 4, 7, 8 and 9 completely sulfated, or KDN (2-keto-3-deoxy-D-glycero-2-nononic acid) having all hydroxyl groups at positions 4, 5, 7, 8 and 9 completely sulfated are provided.

Abstract: An anti-inflammatory drug comprising as the effective component at least one compound selected from the group consisting of colominic acid, partial hydrolysis products of colominic acid and pharmaceutically acceptable salts, thereof. The drug is used as a drug for renal diseases, a drug for hepatitis, an immunomodulator and a drug for inhibiting the chemotaxis of neutrophil.

Abstract: A Lewis-associated compound, represented by general formula (I), a process for producing the same, and an anti-inflammatory, wherein R.sup.1 and R.sup.3 represent each hydrogen, m SO.sub.3 H or CH.sub.2 COOH; R.sup.2 represents hydrogen, SO.sub.3 H, CH.sub.2 COOH or N-acetyl-neutraminic acid residue; R.sup.4 represents hydrogen; R.sup.5 represents O-lower alkyl, O-lower alkenyl, O-ceramide residue, O-mannose residue, O-galactose residue or O-lactose residue; R.sup.6 represents acetylamine; and R.sup.7 and R.sup.8 represent each hydrogen.

Abstract: An anti-inflammatory drug comprising as the effective component at least one compound selected from the group consisting of colominic acid, partial hydrolysis products of colominic acid and pharmaceutically acceptable salts thereof. The drug is used as a drug for renal diseases, a drug for hepatitis, an immunomodulator and a drug for inhibiting the chemotaxis of neutrophil.

Abstract: An anti-inflammatory drug comprising as the effective component at least one compound selected from the group consisting of colominic acid, partial hydrolysis products of colominic acid and pharmaceutically acceptable salts thereof. The drug is used as a drug for renal diseases, a drug for hepatitis, an immunomodulator and a drug for inhibiting the chemotaxis of neutrophil.

Abstract: GM.sub.3 analogous compound (I) below: ##STR1## wherein one of R.sup.2 and R.sup.3 represents a neuramic acid group represented by general formula (V): ##STR2## R.sup.5 represents ##STR3## or hydrogen; R.sup.

Abstract: A monoclonal antibody A exhibits specificity to the sialic acid glycolipid containing the epitope NeuAc.alpha.2.fwdarw.9NeuAc terminal. A monoclonal antibody B exhibits specificity to the sialic acid glycolipid containing the epitope NeuAc.alpha.2.fwdarw.6Gal.beta. terminal. A monoclonal antibody C exhibits specificity to the sialic acid glycolipid containing at least one epitope selected from the group of NeuAc.alpha.2.fwdarw.9NeuAc terminal, NeuAc.alpha.2.fwdarw.6Gal.beta. terminal and NeuAc.alpha.2.fwdarw.1Cer. Hybridomas are prepared which produce antibodies A, B and C. A process for producing the hybridomas is disclosed including the step of fusing a myeloma cell and a B cell (lymphocyte) produced by the immunization of animal using as an antigen, the sialic acid glycolipid containing at least one epitope of the group NeuAc.alpha.2.fwdarw.9NeuAc terminal, NeuAc.alpha.2.fwdarw.6Gal.beta. terminal and NeuAc.alpha.2.fwdarw.1Cer.

Abstract: The present invention relates to ganglioside related compounds having, for example, the following formula: ##STR1## where R.sub.1 represents H or COCH.sub.3 (hereinafter abbreviated to "AC"); R.sub.2 represents H or CH.sub.3 ; and R.sub.3 represents --OH, ##STR2## These ganglioside related compounds are useful as membrane receptors, tumor markers, cell growth controlling substances, etc., and useful for immunotherapy for cancer, etc.

Abstract: The present invention relates to sialic acid derivatives. According to the present invention, there is provided sialic acid derivatives having the general formula (I): ##STR1## wherein, R.sup.1 represents hydrogen, an acetyl group, a trityl group, ##STR2## (R.sup.5 represents hydrogen or an acetyl group and R.sup.6 represents hydrogen, sodium or a methyl group).R.sup.2 represents hydrogen or an acetyl group,one of R.sup.3 and R.sup.4 represents ##STR3## (R.sup.7 represents a hydrogen atom or an acetyl group, R.sup.8 represents a hydrogen atom, an acetyl group or a benzyl group, R.sup.9 represents a hydrogen atom, an acetyl group, a benzyl group or ##STR4## wherein R.sup.10 represents a hydrogen atom or a benzoyl group), while the other represents --COOR.sup.11 wherein R.sup.11 represents hydrogen, sodium, or a methyl group.

Abstract: A sialic acid-bonded octapeptide represented by the following general formula (I): ##STR1## wherein R represents a hydrogen atom or an acetyl group; and R' represents a lower alkyl group, an aralkyl group, a hydrogen atom or an alkali metal atom, is herein disclosed. The peptide chain of the sialic acid-bonded octapeptide is constituted by 8 amino acid molecules on the C-terminus side of FTS and the compounds represented by formula (I) can be obtained by bonding sialic acid to the amino terminus of the peptide chain according to condensation. These octapeptides show excellent physiological activity comparable to FTS and a half life in blood longer than that of FTS and it is expected that the affinity of the peptide to lymphocytes is also enhanced. Thus they can effectively be used as medicines for treating the lowering and abnormality of functions of the thymus.

Abstract: The present invention provides ganglioside-related compounds expressed by the following formula: ##STR1## (wherein R.sub.1 denotes a hydrogen atom or SiR.sub.3 R.sub.4 R.sub.5 (wherein R.sub.3 and R.sub.4 each denotes a methyl or phenyl group, and R.sub.5 denotes a tertiary butyl or dimethylphenylmethyl group), and R.sub.2 denotes a hydrogen atom, a trityl group, or ##STR2## (wherein M denotes an alkali metal atom)) and methods of producing the same. These ganglioside-related compounds are useful as markers for the early detection of cancer and in the immunotherapy for cancer.

Abstract: A sialic acid derivative having an active carbonyl group represented by the formula [I]: ##STR1## wherein R.sup.1 represents hydrogen or acetyl group; R.sup.2 represents hydrogen, a metal or a lower alkyl group; R.sup.3 represents hydrogen, hydroxyl group, or a residue removed hydrogen from an alcohol portion of an active ester; Ac represents acetyl group; and n is 1 to 20, respectively. This sialic acid derivative [I] can be utilized as a starting material for various complex having a sialic acid in the molecule since it has an active carbonyl group in the molecules so that it shows high reactivity.

Abstract: This invention provides a novel compound having a formula such as ##STR1## This invention also provides a process for preparing such a compound.

Abstract: This invention provides a novel compound expressed by the following formula (1): ##STR1## [wherein R.sup.1 denotes a hydrogen atom or CH.sub.3 CO--, R.sup.2 denotes --COOR.sup.4 (R.sup.4 denotes Na or a methyl group) or ##STR2## (R.sup.5 denotes a hydrogen atom, --COC.sub.6 H.sub.5 or --Si(C.sub.6 H.sub.5).sub.2 C(CH.sub.3).sub.3 and R.sup.3 denotes ##STR3## (R.sup.5 denotes a hydrogen atom, --COC.sub.6 H.sub.5 or --Si(C.sub.6 H.sub.5).sub.2 C(CH.sub.3).sub.3) when R.sup.2 is --COOR.sup.4 (R.sup.4 denotes Na or a methyl group) or denotes --COOR.sup.4 when R.sup.2 is ##STR4## and a method of preparation thereof. The above novel compounds of present invention are useful as a tumor maker, a molecular marker for cells having the ability of differential induction, or an intermediate of the synthesis thereof.

Abstract: A sialic acid derivative having an active carbonyl group represented by the formula [I]: ##STR1## wherein R.sup.1 represents hydrogen or acetyl group; R.sup.2 represents hydrogen, a metal or a lower alkyl group; R.sup.3 represents hydrogen, hydroxyl gorup, or a residue removed hydrogen from an alcohol portion of an active ester; Ac represents acetyl group; and n is 1 to 20, respectively. This sialic acid derivative [I] can be utilized as a starting material for various complex having a sialic acid in the molecule since it has an active carbonyl group in the molecules so that it shows high reactivity.